Protein-binding therapy: a new approach to lower cholesterol
- PMID: 39870099
- DOI: 10.1016/S2213-8587(24)00347-4
Protein-binding therapy: a new approach to lower cholesterol
Conflict of interest statement
RAH has served on advisory boards for Acasti, Akcea-Ionis, Amgen, Arrowhead, HLS Therapeutics, Medison, Novartis, Pfizer, Sanofi, Regeneron, and UltraGenyx, and has received honoraria for continuing medical education talks from Amgen, HLS Therapeutics, Novartis, and Pfizer.
Comment on
-
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial.Lancet Diabetes Endocrinol. 2025 Mar;13(3):178-187. doi: 10.1016/S2213-8587(24)00313-9. Epub 2025 Jan 24. Lancet Diabetes Endocrinol. 2025. PMID: 39870096 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
